Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Letter to the Editor

The Number of Antiseizure Medications Taken and not the Lipid Profile was Associated with Seizure Control in Adult Patients with Epilepsy

Author(s): Vania Aparecida Leandro-Merhi*, Glória Maria de Almeida Souza Tedrus, Giovanna Gigolotti Jacober de Moraes and Michele Novaes Ravelli

Volume 23, Issue 8, 2024

Published on: 22 August, 2023

Page: [927 - 930] Pages: 4

DOI: 10.2174/1871527323666230816090102

conference banner
Abstract

Previous studies show changes in lipid metabolism in epilepsy. The aim of this study was to investigate the association between lipid profile and clinical variables in adult patients with epilepsy (APE). Seventy-two APE participated in this pilot study at an outpatient neurology service. The lipid profile (total cholesterol, low-density lipoprotein (LDL) cholesterol, very-low-density lipoproteins (VLDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides), age at disease onset, disease duration, seizures frequency, and the number of antiseizure medications (ASM) used were investigated. Data were analyzed using the Chi-square, Fisher, Mann-Whitney, Spearman coefficient, and logistic regression tests. There were significant differences in HDL (p = 0.0023) and total cholesterol (p = 0.0452) levels in connection with the number of ASM used. There was a significant difference in seizure control among the different numbers of ASM used (p = 0.0382). Higher HDL values were found in females (p = 0.0170). The logistic regression showed that only the number of ASM used was associated with seizure control (p = 0.0408; OR = 2.800; 95% CI = 1.044; 7.509). The number of ASM taken and not the lipid profile was associated with seizure control in APE.

Keywords: Lipid metabolism, seizure control, number of antiseizure medications (ASM), epilepsy, ketogenic diet, metabolic.

« Previous Next »
[1]
van Berkel AA, IJff DM, Verkuyl JM. Cognitive benefits of the ketogenic diet in patients with epilepsy: A systematic overview. Epilepsy Behav 2018; 87: 69-77.
[http://dx.doi.org/10.1016/j.yebeh.2018.06.004] [PMID: 30173019]
[2]
Kossoff EH, Zupec-Kania BA, Amark PE, et al. Optimal clinical management of children receiving the ketogenic diet: Recommendations of the International Ketogenic Diet Study Group. Epilepsia 2009; 50(2): 304-17.
[http://dx.doi.org/10.1111/j.1528-1167.2008.01765.x] [PMID: 18823325]
[3]
Neal EG, Zupec-Kania B, Pfeifer HH. Carnitine, nutritional supplementation and discontinuation of ketogenic diet therapies. Epilepsy Res 2012; 100(3): 267-71.
[http://dx.doi.org/10.1016/j.eplepsyres.2012.04.021] [PMID: 22704584]
[4]
Chukwu J, Delanty N, Webb D, Cavalleri GL. Weight change, genetics and antiepileptic drugs. Expert Rev Clin Pharmacol 2014; 7(1): 43-51.
[http://dx.doi.org/10.1586/17512433.2014.857599] [PMID: 24308788]
[5]
Choi H, Elkind MSV, Longstreth WT Jr, et al. Epilepsy, vascular risk factors, and cognitive decline in older adults: The cardiovascular health study. Neurology 2022; 99(21)
[http://dx.doi.org/10.1212/WNL.0000000000201187] [PMID: 36240101]
[6]
Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58(4): 522-30.
[http://dx.doi.org/10.1111/epi.13670] [PMID: 28276060]
[7]
Faludi AA, Izar MCO, Saraiva JFK, Chacra APM, Bianco HT, Afiune A. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose - 2017. Arq Bras Cardiol 2017; 109(2) (Suppl. 1): 1-76.
[http://dx.doi.org/10.5935/abc.20170121]
[8]
Zuberi NA, Baig M, Bano S, Batool Z, Haider S, Perveen T. Assessment of atherosclerotic risk among patients with epilepsy on valproic acid, lamotrigine, and carbamazepine treatment. Neurosciences 2017; 22(2): 114-8.
[http://dx.doi.org/10.17712/nsj.2017.2.20160342] [PMID: 28416782]
[9]
Nunes VS, da Silva Ferreira G, Quintão ECR. Cholesterol metabolism in aging simultaneously altered in liver and nervous system. Aging 2022; 14(3): 1549-61.
[http://dx.doi.org/10.18632/aging.203880] [PMID: 35130181]
[10]
Kurul S, Ünalp A, Yiş U. Homocysteine levels in epileptic children receiving antiepileptic drugs. J Child Neurol 2007; 22(12): 1389-92.
[http://dx.doi.org/10.1177/0883073807307081] [PMID: 18174557]
[11]
Calik M, Ozkan HY, Ethemoglu O, et al. The measurement of both carotid intima-media thickness and epicardial adipose tissue thickness in children with epilepsy receiving antiepileptic drug therapy. Epilepsy Behav 2018; 85: 110-4.
[http://dx.doi.org/10.1016/j.yebeh.2018.05.042] [PMID: 29940373]
[12]
Mahrous DM, Moustafa AN, Higazi MM, Higazi AM, AbdelAziz RA. Influence of different antiseizure medications on vascular risk factors in children with epilepsy. Children 2022; 9(10): 1499.
[http://dx.doi.org/10.3390/children9101499] [PMID: 36291435]
[13]
Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch Neurol 2010; 67(12): 1491-7.
[http://dx.doi.org/10.1001/archneurol.2010.297] [PMID: 21149810]
[14]
Barzilai N, Atzmon G, Derby CA, Bauman JM, Lipton RB. A genotype of exceptional longevity is associated with preservation of cognitive function. Neurology 2006; 67(12): 2170-5.
[http://dx.doi.org/10.1212/01.wnl.0000249116.50854.65] [PMID: 17190939]

Rights & Permissions Print Cite
Article Metrics
13
1
Wayfinder Image
World Patient Safety Day
© 2024 Bentham Science Publishers | Privacy Policy